Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
NNOX
Nano-X Imaging Ltd.
Directly manufactures diagnostic imaging equipment used for disease detection and monitoring.
|
$201.28M |
$3.15
+2.61%
|
|
CABA
Cabaletta Bio, Inc.
Core product category: CAR-T cell therapy platform (CARTA) and rese-cel directly produced by Cabaletta.
|
$201.22M |
$2.21
+6.25%
|
|
WALD
Waldencast plc
FDA-approved Obagi saypha MagIQ injectable gel indicates a dermal filler/medical device product line.
|
$201.22M |
$1.63
-1.21%
|
|
SGMT
Sagimet Biosciences Inc.
Sagimet's lead and second FASN inhibitors (denifanstat, TVB-3567) are oral small-molecule therapeutics, directly aligning with this tag.
|
$199.68M |
$6.16
-1.68%
|
|
AVTX
Avalo Therapeutics, Inc.
AVTX-9.00 is an anti-IL-1β monoclonal antibody, directly fitting Monoclonal Antibody Therapeutics.
|
$198.07M |
$15.03
-3.90%
|
|
OSUR
OraSure Technologies, Inc.
OraSure's core offerings include diagnostic equipment such as OraQuick rapid tests and molecular diagnostics platforms.
|
$196.74M |
$2.69
-1.82%
|
|
UTMD
Utah Medical Products, Inc.
Filshie Clip System is a surgical device used in gynecologic procedures, directly aligning with UTMD's Filshie Clip product line.
|
$196.03M |
$61.39
+1.86%
|
|
DERM
Journey Medical Corporation
Emrosi is an oral small molecule therapeutic (minocycline extended-release) and represents Journey Medical's flagship product launched in 2025.
|
$195.27M |
$8.01
-4.19%
|
|
GALT
Galectin Therapeutics Inc.
Lead cancer therapy program belapectin demonstrates oncology-focused Biotech activity and immuno-oncology potential.
|
$194.74M |
$3.04
-3.33%
|
|
SLGL
Sol-Gel Technologies Ltd.
Proprietary microencapsulation drug-delivery platform is a core technology Sol-Gel uses to formulate topical therapies.
|
$193.61M |
$68.59
+0.41%
|
|
TARA
Protara Therapeutics, Inc.
TARA-2.00 is a cell therapy platform, representing the company’s lead product modality.
|
$193.30M |
$5.01
-0.50%
|
|
RNAC
Cartesian Therapeutics, Inc.
Lead platform is an autologous cell therapy using mRNA CAR-T, a direct cell-therapy product line.
|
$192.94M |
$7.41
+0.68%
|
|
CRDF
Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company focused on oncology therapeutics, with its lead asset targeting cancer (onvansertib).
|
$191.59M |
$2.89
+3.58%
|
|
SKIN
The Beauty Health Company
High-margin disposable consumables (tips, solutions, serums) sold for Hydrafacial devices create a recurring revenue stream, matching Medical Device Consumables.
|
$190.24M |
$1.50
-3.85%
|
|
IMDX
Insight Molecular Diagnostics Inc.
IMDX directly provides Laboratory Testing & Advisory Services via its GraftAssure family (LDTs/kits) for transplant rejection monitoring.
|
$189.89M |
$6.61
-0.23%
|
|
CBIO
Crescent Biopharma, Inc.
Crescent Biopharma focuses on oncology therapeutics, explicitly mentioning next-gen cancer biologics and its lead PD-1 x VEGF bispecific and ADCs.
|
$187.69M |
$13.45
+7.56%
|
|
NYXH
Nyxoah S.A.
Genio is a neuromodulation implant system (implantable medical device) for obstructive sleep apnea.
|
$187.55M |
$5.17
+0.39%
|
|
CNFN
CFN Enterprises Inc.
CNFN's Ranco segment operates as a contract manufacturer/co-packer and white-label producer for clients.
|
$186.35M |
$1.57
|
|
ALEC
Alector, Inc.
Latozinemab and AL101 are monoclonal antibody therapeutics in the pipeline.
|
$186.23M |
$1.84
+1.10%
|
|
CHRS
Coherus Oncology, Inc.
LOQTORZI is a differentiated PD-1 monoclonal antibody and commercial oncology product, aligning with Monoclonal Antibody Therapeutics.
|
$185.96M |
$1.61
-3.01%
|
|
RPID
Rapid Micro Biosystems, Inc.
Growth Direct is a diagnostic equipment platform for automated microbial detection used in pharmaceutical QC.
|
$184.80M |
$4.18
+21.16%
|
|
INFU
InfuSystem Holdings, Inc.
InfuSystem directly provides infusion pumps and related medical device equipment, plus lifecycle management services.
|
$179.34M |
$8.83
+2.67%
|
|
EDIT
Editas Medicine, Inc.
Core product category: in vivo gene therapy using Editas's gene-editing platform (AsCas12a) delivered via targeted lipid nanoparticles (tLNP).
|
$178.94M |
$2.04
+2.76%
|
|
AVR
Anteris Technologies Global Corp.
Company directly develops and sells medical devices for the cardiovascular field, specifically the DurAVR transcatheter heart valve and related biomaterial technologies.
|
$178.87M |
$4.91
-1.01%
|
|
LFMD
LifeMD, Inc.
LifeMD operates as a healthcare services provider with a multi-state medical group and in-house pharmacy; core service delivery.
|
$178.76M |
$3.78
+0.27%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA's lead product Foralumab is a fully human monoclonal antibody therapeutic, placing the company in Monoclonal Antibody Therapeutics.
|
$177.91M |
$1.68
+15.52%
|
|
PRQR
ProQR Therapeutics N.V.
ProQR's Axiomer platform uses oligonucleotide-based RNA editing (EONs) to direct ADAR-mediated editing.
|
$177.72M |
$1.67
+5.38%
|
|
TKNO
Alpha Teknova, Inc.
Teknova is the exclusive US/Canada manufacturer and distributor of the PluriFreeze PF10 cryopreservation system, a medical device.
|
$177.67M |
$3.31
-10.54%
|
|
PERF
Perfect Corp.
HD skin diagnostics deployed in aesthetic clinics, representing healthcare-oriented diagnostic software.
|
$177.22M |
$1.74
+1.46%
|
|
MDWD
MediWound Ltd.
MediWound's core products are enzymatic proteins/enzymes (NexoBrid, EscharEx) used for wound debridement, aligning with Recombinant Proteins & Enzymes.
|
$176.73M |
$16.32
-6.04%
|
|
CRBU
Caribou Biosciences, Inc.
Company is developing gene-editing gene therapy platforms (CRISPR-based chRDNA) for therapeutic applications.
|
$176.00M |
$1.85
-2.12%
|
|
HUMA
Humacyte, Inc.
Humacyte's Symvess is a vascular conduit/endovascular device used for extremity vascular trauma—fits Vascular Intervention Devices.
|
$175.79M |
$1.11
+1.36%
|
|
MIST
Milestone Pharmaceuticals Inc.
Milestone's lead candidate etripamil is a cardiovascular drug developed for PSVT and AFib-RVR.
|
$174.24M |
$2.23
+9.02%
|
Showing page 22 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
